Therapeutics News and Research

RSS

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

SRI International has been awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse to conduct preclinical safety studies of potential new medications to treat substance abuse. SRI researchers will study potential drug-drug interactions between new treatment therapies and common drugs of abuse to assess potential adverse reactions.

6 Nov 2013

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

6 Nov 2013

ImmunoGen decides to stop IMGN901 Phase II SCLC study

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee.

6 Nov 2013

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Transferring the gut microbes from a mouse with colon tumors to germ-free mice makes those mice prone to getting tumors as well, according to the results of a study published in mBio-, the online open-access journal of the American Society for Microbiology.

6 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

Scientists map structure of key part of immune system responsible for neutralizing bacteria, viruses

Leicester scientists have mapped the "bouquet-like" structure of a key part of the body's immune system responsible for neutralising bacteria and viruses.

5 Nov 2013

Zevacor Molecular buys 70 MeV Cyclotron dedicated to medical use from IBA

Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A.

5 Nov 2013

SRI to expand current preclinical molecular imaging capabilities with MILabs VECTor+ system

MILabs is pleased to announce that Sunnybrook Research Institute, the research arm of the Sunnybrook Health Sciences Centre, located in Toronto, Canada will install a MILabs VECTor+ system to expand their current preclinical molecular imaging capabilities.

4 Nov 2013

Current percutaneous techniques shed light on treatment of heart valve leakage

A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference.

4 Nov 2013

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company's ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).

31 Oct 2013

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.

31 Oct 2013

Results of Nordic-Baltic Bifurcation IV trial presented at TCT 2013

A new clinical trial shows that a two-stent technique for treatment of bifurcation lesions with a large stenotic side branch was not associated with significant improved outcomes compared to a provisional stenting approach.

31 Oct 2013

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

The National Cancer Institute's (NCI) new Provocative Questions research funding program has awarded a prestigious grant to a researcher at Roswell Park Cancer Institute (RPCI) to investigate a promising but neglected or unexplored area of cancer research.

31 Oct 2013

New insights into human cytomegalovirus may lead to development of therapeutic interventions

New insights into how human cytomegalovirus, the leading cause of birth defects associated with infection spreads from pregnant mother to fetus and from organ to organ in newborns provides translational researchers an exciting new avenue for investigation that may lead to the development of therapeutic interventions.

31 Oct 2013

UofL researcher enters into license and research collaboration agreement with Novartis

The University of Louisville today announced that researcher Dr. Suzanne Ildstad, representing Regenerex LLC, has entered into a license and research collaboration agreement with Novartis to provide access to stem cell technology that has the potential to help transplant patients avoid taking anti-rejection medicine for life and could serve as a platform for treatment of other diseases.

31 Oct 2013

Wrist artery for coronary angioplasty may benefit women at high risk of blood loss

For women who are at high risk of blood loss, using an artery in the wrist may be better than the groin for routing a stent to the heart during coronary angioplasty, according to researchers at Duke Medicine.

30 Oct 2013

ETPN organizes Nanomedicine Award to honor the best international innovation for 2013

Since the official launch in June 2013, the European Technology Platform for Nanomedicine (ETPN) together with the EU funded consortium NANOMED2020, are organising the first ever Nanomedicine Award to honor the best international nanomedicine innovation for 2013!

30 Oct 2013

Clinical trial finds COREVALVE reduces rate of death, stroke in patients with aortic stenosis

In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery.Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

30 Oct 2013

Therapeutics News and Research

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen decides to stop IMGN901 Phase II SCLC study

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

NTU establishes new $60 million research institute in Nanomedicine

Scientists map structure of key part of immune system responsible for neutralizing bacteria, viruses

Zevacor Molecular buys 70 MeV Cyclotron dedicated to medical use from IBA

SRI to expand current preclinical molecular imaging capabilities with MILabs VECTor+ system

Current percutaneous techniques shed light on treatment of heart valve leakage

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

Results of Nordic-Baltic Bifurcation IV trial presented at TCT 2013

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

New insights into human cytomegalovirus may lead to development of therapeutic interventions

UofL researcher enters into license and research collaboration agreement with Novartis

Wrist artery for coronary angioplasty may benefit women at high risk of blood loss

ETPN organizes Nanomedicine Award to honor the best international innovation for 2013

Clinical trial finds COREVALVE reduces rate of death, stroke in patients with aortic stenosis

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News